Added to YB: 2026-05-22
Pitch date: 2026-05-20
CRBP [bullish]
Corbus Pharmaceuticals Holdings, Inc.
+16.26%
current return
Author Info
No bio for this author
Company Info
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Market Cap
$202.7M
Pitch Price
$9.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.75
P/E
-2.02
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Corbus Pharmaceuticals Holdings, Inc. - $CRBP
CRBP: ASCO abstract Thursday 5PM ET will show mature HPV-stratified data for Nectin-4 ADC CRB-701 in HNSCC. HPV+ oropharyngeal segment (~30-40% of HNSCC) is weak point for EGFR therapies (peto 13% ORR vs 36% overall; rivals exclude HPV+ from pivotal trials). Early data: 9/11 p16+ patients responded (81.8% cORR vs 23.3% HPV-). 2L addressable market ~$1B TAM. Downside limited at $7.38 cash/share. Risk: Pfizer discontinued similar PD-L1 ADC in HNSCC.
Read full article (4 min)